管理化脓性汗腺炎（HS）需要一种多方面的方法，包括医疗、外科和社会干预来为患者服务。
诊断化脓性汗腺炎（HS）临床医生应注意2-2-6规则：6个月内出现2次或2次以上脓肿。
阿达木单抗是一种TNF抑制剂，广泛用于HS。根据2项3期试验的数据，约40-60%的患者对阿达木单抗有反应。然而，大约40-50%的患者在9个月内失去反应。增加治疗失败风险的因素包括晚期疾病（Hurley III期）、排水隧道的存在、肥胖和吸烟。阿达木单抗在围手术期使用是安全的，剂量增加可能是有益的，尽管这方面的数据有限。
Secukinumab是一种IL-17A抑制剂，对对TNF抑制剂没有反应的患者显示出前景。推荐剂量为：每周皮下注射300 mg，持续5周，然后每4或2周注射300 mg。女性和BMI较低的患者往往反应更好。值得注意的是，大约60%的TNF抑制剂失效在16周时有反应。secukinumab对有脱髓鞘性疾病、心力衰竭或恶性病史的患者特别有用。
Bimekizumab靶向IL-17A和IL-17F，证明有效。在试验中，在最高剂量下，16周时的BE HEARD HiSCR50反应约为55%至60%，48周时的反应约为70%。这种双重抑制策略为更严重或难治性HS患者带来了希望。
波伏西替尼（Povorcitinib）是一种JAK1抑制剂，在II期试验中显示出潜力，在12周前最高剂量时，HiSCR50评分显示约60%，在12周前最高剂量下，HiSCR90评分显示约20%。其机制涉及下调TNF-α和TGF-β途径，为HS管理提供了一种新的治疗途径。
资料来源
A clinician’s guide to managing hidradenitis suppurativa: an in-depth workshop. Presented at: 2024 Fall Clinical Dermatology Conference for PAs and NPs; May 31-June 2, 2024;
Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2022;86(5):1092-1101.
The most recent advances in understanding and managing hidradenitis suppurativa. F1000Res. 2020;9:F1000 Faculty Rev-1049. Published 2020 Aug 26.
Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial. JAMA Surg. 2021;156(11):1001-1009.
Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422-434.
short-term effectiveness, safety, and potential predictors of response of secukinumab in patients with severe hidradenitis suppurativa refractory to biologic therapy: a multicenter observational retrospective study. Dermatol Ther (Heidelb). 2023;13(4):1029-1038.
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials [published correction appears in Lancet. 2024 Feb 17;403(10427):618]. Lancet. 2023;401(10378):747-761.
Bimekizumab in patients with moderate-to-severe hidradenitis suppurativa: 48-week efficacy and safety from BE HEARD I & II, two phase 3, randomized, double-blind, placebo controlled, multicenter studies. Presented at Late-breaking Research Session 1 of the Annual Academy of Dermatology Annual Meeting. March 17-21, 2023; New Orleans, LA.
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2024;90(3):521-529.
Wound care for patients with hidradenitis suppurativa: Recommendations of an international panel of experts. J Am Acad Dermatol. 2023;89(6):1289-1292.
